Duke University School of Medicine

Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)

Retrieved on: 
Mercoledì, Agosto 4, 2021
Medical specialties, Health sciences, Health, Immunology, RVT-802, Thymus, Food and Drug Administration, Clinical trial

CAMBRIDGE, Mass. and BASEL, Switzerland, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Positive results from clinical trials of Enzyvant’s investigational RVT-802 (allogeneic processed thymus tissue-agdc), engineered human thymus tissue implanted in 105 pediatric patients, were published today in The Journal of Allergy and Clinical Immunology.1

Key Points: 
  • These data suggest we are on the threshold of a brighter day for pediatric patients with congenital athymia.
  • Engineered human thymus tissue has been studied by researchers across 10 clinical studies at a single center for more than 25 years.
  • Ninety-five patients were included in the Efficacy Analysis Set (EAS) and 105 patients were included in the Safety Analysis Set.
  • Enzyvants lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency.

Biomedical Informatics Leader Erich Huang Joins Onduo as Chief Science and Innovation Officer

Retrieved on: 
Lunedì, Giugno 7, 2021
Data management, Biotechnology, Technology, Other Health, Diabetes, Health, General Health, Mental health, Other Science, Software, Science, Duke University School of Medicine, Health informatics, Huang

Onduo today announced the appointment of Erich S. Huang MD, PhD, to the position of Chief Science and Innovation Officer.

Key Points: 
  • Onduo today announced the appointment of Erich S. Huang MD, PhD, to the position of Chief Science and Innovation Officer.
  • Dr. Huang joins Onduo from Duke where he served as the Chief Data Officer for Quality in Duke Health, Director of Duke Forge, Director of Duke Crucible, and Assistant Dean for Biomedical Informatics for Duke University School of Medicine.
  • View the full release here: https://www.businesswire.com/news/home/20210607005454/en/
    Erich S. Huang, MD, PhD, joins Onduo as Chief Science and Innovation Officer to lead evidence generation activities and drive its population health innovation efforts through applied data science and predictive modeling development.
  • Dr. Erich S. Huang is the Chief Science and Innovation Officer at Onduo.

Joseph G. Rogers, MD, elected president of ISHLT

Retrieved on: 
Martedì, Maggio 19, 2020
Medical specialties, Transplantation medicine, International Society for Heart and Lung Transplantation, Surgery, Duke University School of Medicine, Organ transplantation, Duke University Health System, Leslie W. Miller, Michael L. Hess

Addison, Texas, May 19, 2020 (GLOBE NEWSWIRE) -- Joseph G. Rogers, MD, cardiologist, Professor of Medicine at the Duke University School of Medicine and Chief Medical Officer at the Duke University Health System, Durham, NC, has been elected President of the International Society for Heart and Lung Transplantation (ISHLT).

Key Points: 
  • Addison, Texas, May 19, 2020 (GLOBE NEWSWIRE) -- Joseph G. Rogers, MD, cardiologist, Professor of Medicine at the Duke University School of Medicine and Chief Medical Officer at the Duke University Health System, Durham, NC, has been elected President of the International Society for Heart and Lung Transplantation (ISHLT).
  • Dr. Rogers will serve a one-year term as President through the 2021 Annual Meeting, to be held in Toronto April 27-30.
  • I am honored to serve and lead ISHLT, Rogers said.
  • ISHLT is the worlds largest multi-disciplinary organization committed to improving the care of patients with advanced heart and lung disease.

Duke Clinical Research Institute to Expedite Study of COVID-19 Prevention in Healthcare Workers

Retrieved on: 
Mercoledì, Aprile 1, 2020
Duke University School of Medicine, V-12 Navy College Training Program, Clinical research

"Furthermore, the HERO registry of healthcare workers will ease study start-up times for future clinical trials that may be carried out for other prevention or treatment strategies."

Key Points: 
  • "Furthermore, the HERO registry of healthcare workers will ease study start-up times for future clinical trials that may be carried out for other prevention or treatment strategies."
  • The DCRI, part of the Duke University School of Medicine, is the largest academic clinical research organization in the world.
  • Adrian Hernandez, MD, MHS, who initiated the HERO program, serves as Vice Dean for Clinical Research in the Duke University School of Medicine.
  • Susanna Naggie, MD, who is leading the HERO-HCQ trial, serves as Associate Dean for Clinical Research Initiatives and Regulatory Affairs.

Verana Health Appoints Veteran Cardiologist and Clinical Researcher, Dr. Matthew Roe, as Chief Medical Officer

Retrieved on: 
Giovedì, Febbraio 20, 2020
Technology, Research, Clinical trials, Software, Biotechnology, Health, Pharmaceutical, Data management, Science, V-12 Navy College Training Program, Roe, Duke University School of Medicine, Physician-scientist

Verana Health today announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer.

Key Points: 
  • Verana Health today announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer.
  • A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over two decades at the Duke University School of Medicine and the Duke Clinical Research Institute (DCRI), the world's largest academic clinical research organization.
  • Dr. Roe is an acclaimed physician-scientist with over two decades of experience focused on the intersection of patient care and real-world data; a complete alignment with the clinical efforts of Verana Health, said Miki Kapoor, CEO of Verana Health.
  • As Chief Medical Officer, Dr. Roe will lead Veranas medical and data science teams working to ensure the clinical validity and scientific integrity of its research.

Research Network Based at Duke Clinical Research Institute Awarded up to $102.5M for Work on Antibacterial Resistance

Retrieved on: 
Venerdì, Dicembre 13, 2019
Health, Articles, Clinical pharmacology, Healthcare quality, Duke University School of Medicine, V-12 Navy College Training Program, Outcomes research, Clinical trial, Disease registry, Antibiotic

Antibacterial treatments are becoming less effective, resulting in an urgent threat to public health.

Key Points: 
  • Antibacterial treatments are becoming less effective, resulting in an urgent threat to public health.
  • The DCRI, part of the Duke University School of Medicine, is the largest academic research organization in the world.
  • Its mission is to develop and share knowledge that improves the care of patients through innovative clinical research.
  • The institute conducts groundbreaking multinational clinical trials, manages major national patient registries, and performs landmark outcomes research.

Amgen And The Duke Clinical Research Institute Announce Initiation Of First Large-Scale Registry To Evaluate Real-World Lipid Management And The Effectiveness Of PCSK9 Inhibitors

Retrieved on: 
Venerdì, Novembre 15, 2019
Clinical research, Health, Design of experiments, Medical research, Medical statistics, PCSK9, Clinical trial, Duke University School of Medicine, Pragmatic clinical trial

A prospective observational registry of 8,500 adults eligible for treatment with a PCSK9 inhibitor will be followed for five years.

Key Points: 
  • A prospective observational registry of 8,500 adults eligible for treatment with a PCSK9 inhibitor will be followed for five years.
  • This should help set the stage for future big data analyses and pragmatic clinical trials," said Dr. Peterson.
  • The study will be the first to investigate long-term outcomes in this population with Repatha for a minimum of four years.
  • The DCRI, part of the Duke University School of Medicine, is the largest academic research organization in the world.

Cerner, Duke Clinical Research Institute Launch New Solution to Innovate Clinical Research

Retrieved on: 
Martedì, Agosto 6, 2019
Health, Articles, V-12 Navy College Training Program, Health informatics, Duke University School of Medicine, Cerner, Disease registry

Through combined technology and expertise, Cerner and the Duke Clinical Research Institute (DCRI) have joined together to pilot the Cerner Learning Health Network and innovate clinical research registries in the process.

Key Points: 
  • Through combined technology and expertise, Cerner and the Duke Clinical Research Institute (DCRI) have joined together to pilot the Cerner Learning Health Network and innovate clinical research registries in the process.
  • The automation and streamlining of health data for clinical research has the potential to speed innovation and life-saving insights.
  • The DCRI conducts groundbreaking multinational clinical trials, manages major national patient registries, and performs landmark outcomes research.
  • DCRI research spans multiple disciplines, from pediatrics to geriatrics, primary care to subspecialty medicine, and genomics to proteomics.

Reflexion Health and Duke Clinical Research Institute Announce Results of the First Randomized Controlled Trial Demonstrating Virtual Physical Therapy Outperforms Traditional Approach

Retrieved on: 
Lunedì, Ottobre 15, 2018
Health, Medicine, Drug discovery, Rehabilitation medicine, Clinical research, Physical exercise, Physical therapy, Therapy, Clinical trial, Duke University School of Medicine

SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- ReflexionHealth ,the virtual rehabilitation therapy company, in conjunction with the Duke Clinical Research Institute (DCRI), today announced positive results from a randomized controlled clinical trial, "Virtual Exercise Rehabilitation In-home Therapy: A Research Study (VERITAS)."

Key Points: 
  • SAN DIEGO, Oct. 15, 2018 /PRNewswire/ -- ReflexionHealth ,the virtual rehabilitation therapy company, in conjunction with the Duke Clinical Research Institute (DCRI), today announced positive results from a randomized controlled clinical trial, "Virtual Exercise Rehabilitation In-home Therapy: A Research Study (VERITAS)."
  • Conducted independently by the DCRI, VERITAS is the first large-scale randomized controlled clinical trial that compares virtual physical therapy with traditional physical therapy.
  • The study results demonstrated an average cost savings of $2,745 per patient for those who received virtual physical therapy using VERA technology with clinical oversight when compared to usual care with traditional physical therapy.
  • The Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine, is the largest academic research organization in the world.